Adverse Drug Reactions to Antifungals Used in the Management of COVID-19 Associated Rhino-Orbito-Cerebral Mucormycosis

Simple item page
dc.contributor.authorTiwari, Sen_US
dc.contributor.authorVakil, Z.en_US
dc.date.accessioned2023-06-17T07:12:23Z
dc.date.available2023-06-17T07:12:23Z
dc.date.issued2022-07
dc.description.abstractObjectives: To determine the incidence and frequency of adverse drug reactions (ADRs) to find out factors, if any contributing to the same, while also exploring the use of amphotericin B deoxycholate as a cheaper and safe alternative to liposomal amphotericin B. Materials and Methods: It was a cross-sectional observational study, with a study population of 50 conducted over three months after ethics approval. All adult patients admitted to a tertiary care center, in a metropolitan city of Maharashtra, diagnosed with Rhino-orbito-cerebral mucormycosis, with a history of previous COVID-19 infection and receiving antifungals for the treatment of the same were included in the study. Central Drugs Standard Control Organization (CDSCO) ADR reporting forms were used to collect data. Results: Electrolyte disturbances mainly hypokalemia were the most frequently encountered ADR with both Amphotericin formulations (39/50; 20.31%) followed by pain at the injection site (33/50; 17.19%). Nephrotoxicity occurred slightly more frequently with Amphotericin B Deoxycholate (19/29; 65%), compared to Liposomal Amphotericin B (11/19; 57%), while Posaconazole was mainly associated with gastrointestinal (GI) disturbances and hepatotoxicity. Conclusion: Amphotericin B Deoxycholate was associated most with ADRs, hypokalemia, and pain at the injection site being the most frequent. However, concerning nephrotoxicity, both Amphotericin formulations showed only a modest difference. Posaconazole was associated with the least number of ADRs and had a favorable safety profile.en_US
dc.identifier.affiliationsDepartment of General Medicine, Seth GS Medical College and KEM Hospital, Parel, Mumbai, Maharashtra, Indiaen_US
dc.identifier.affiliationsDepartment of General Medicine, Seth GS Medical College and KEM Hospital, Parel, Mumbai, Maharashtra, India.en_US
dc.identifier.citationTiwari S, Vakil Z.. Adverse Drug Reactions to Antifungals Used in the Management of COVID-19 Associated Rhino-Orbito-Cerebral Mucormycosis. Journal of Pharmacology and Pharmacotherapeutics. 2022 Jul; 13(2): 197–202en_US
dc.identifier.issn0976-500X
dc.identifier.issn0976-5018
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/216053
dc.languageenen_US
dc.publisherSAGE Publicationsen_US
dc.relation.issuenumber2en_US
dc.relation.volume13en_US
dc.source.urihttps://doi.org/10.1177/0976500X221105759en_US
dc.subjectSystemic antifungalsen_US
dc.subjectCAMen_US
dc.subjectAdverse effectsen_US
dc.subjectNephrotoxicityen_US
dc.subjectCOVID-19en_US
dc.subjectEpidemicen_US
dc.subjectAmphotericin B Deoxycholateen_US
dc.subjectPosaconazoleen_US
dc.subjectLiposomal Amphotericin Ben_US
dc.titleAdverse Drug Reactions to Antifungals Used in the Management of COVID-19 Associated Rhino-Orbito-Cerebral Mucormycosisen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
JPP2022v13n2p197.pdf
Size:
233.44 KB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Pharmacology and Pharmacotherapeutics